{"id":"nemonapride","rwe":[{"pmid":"39856236","year":"2025","title":"Exploring the impact of deleterious missense nonsynonymous single nucleotide polymorphisms in the DRD4 gene using computational approaches.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"39341503","year":"2024","title":"Effects of dopamine receptor antagonists and radiation on mouse neural stem/progenitor cells.","finding":"","journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","studyType":"Clinical Study"},{"pmid":"36712018","year":"2023","title":"Effects of Dopamine Receptor Antagonists and Radiation on Mouse Neural Stem/Progenitor Cells.","finding":"","journal":"bioRxiv : the preprint server for biology","studyType":"Clinical Study"},{"pmid":"36637685","year":"2023","title":"Agonistic properties of a series of psychotropic drugs at 5-HT(1A) receptors in rat and human brain membranes determined by [(35)S]GTPγS binding assay.","finding":"","journal":"Pharmacological reports : PR","studyType":"Clinical Study"},{"pmid":"35545150","year":"2022","title":"Interaction of the preferential D(3) agonist (+)PHNO with dopamine D(3)-D(2) receptor heterodimers and diverse classes of monoamine receptor: relevance for PET imaging.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"nemonapride","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D(4) dopamine receptor","category":"target"},{"label":"DRD4","category":"gene"},{"label":"DRD3","category":"gene"},{"label":"DRD2","category":"gene"},{"label":"Active","category":"status"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"emonapride","offLabel":[],"synonyms":["nemonapride","emonapride"],"timeline":[],"approvals":[],"brandName":"Emonapride","ecosystem":[],"mechanism":{"target":"D(4) dopamine receptor, Transmembrane protein 97, D(2) dopamine receptor","targets":[{"gene":"DRD4","source":"DrugCentral","target":"D(4) dopamine receptor","protein":"D(4) dopamine receptor"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"TMEM97","source":"DrugCentral","target":"Transmembrane protein 97","protein":"Transmembrane protein 97"}],"modality":"Small Molecule","drugClass":"nemonapride","explanation":"Imagine your brain is like a city with many different streets. Dopamine is like a busy highway that carries important messages. When there's too much traffic on this highway, it can cause problems. Emonapride is like a traffic cop that blocks the highway, reducing the amount of traffic and helping to calm things down.","oneSentence":"Emonapride works by blocking the D(4) dopamine receptor, which can help to reduce excessive dopamine activity in the brain.","technicalDetail":"Emonapride acts as a selective antagonist at the D(4) dopamine receptor, which is a subtype of dopamine receptor found in the brain. This action can help to reduce the activity of dopamine in certain areas of the brain, which can be beneficial for treating conditions such as schizophrenia and other psychiatric disorders."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Nemonapride","title":"Nemonapride","extract":"Nemonapride, also previously known as emonapride and sold under the brand name Emilace, is an atypical antipsychotic which is used in the treatment of schizophrenia. It is taken by mouth.","wiki_history":"== History ==\nNemonapride was developed by scientists at Yamanouchi Pharmaceuticals via structural modification of the benzamide antiemetic and gastroprokinetic agent metoclopramide. It was first described in the scientific literature by 1980. The name nemonapride was first used by 1989 and this name was designated as its  in 1991. The drug was launched in May 1991. However, other sources state that it was launched in 1997.","wiki_society_and_culture":"== Society and culture ==\n=== Names ===\nNemonapride is the generic name of the drug and its  and . It was also previously known as emonapride and by its former developmental code name YM 09151-2. In addition, nemonapride is known by its brand name Emilace (: エミレース) in Japan and China.\n\n=== Availability ===\nNemonapride is marketed only in Japan and China. It was also under development for use in other countries, such as France, but development in other countries was discontinued. There are no further plans for nemonapride to be developed for use in the United States, the United Kingdom, or Europe."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1895","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NEMONAPRIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Nemonapride","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T14:37:57.256040","biosimilars":[],"competitors":[{"drugName":"acepromazine","drugSlug":"acepromazine","fdaApproval":"","relationship":"same-target"},{"drugName":"acetophenazine","drugSlug":"acetophenazine","fdaApproval":"1961-04-05","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amisulpride","drugSlug":"amisulpride","fdaApproval":"2020-02-26","patentExpiry":"Mar 10, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"apomorphine","drugSlug":"apomorphine","fdaApproval":"2004-04-20","patentExpiry":"Jun 11, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"aripiprazole lauroxil","drugSlug":"aripiprazole-lauroxil","fdaApproval":"2015-10-05","patentExpiry":"Sep 8, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"armodafinil","drugSlug":"armodafinil","fdaApproval":"2007-06-05","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"nemonapride","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"acepromazine","brandName":"acepromazine","genericName":"acepromazine","approvalYear":"","relationship":"same-target"},{"drugId":"acetophenazine","brandName":"acetophenazine","genericName":"acetophenazine","approvalYear":"1961","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amisulpride","brandName":"amisulpride","genericName":"amisulpride","approvalYear":"2020","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-target"},{"drugId":"apomorphine","brandName":"apomorphine","genericName":"apomorphine","approvalYear":"2004","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"aripiprazole-lauroxil","brandName":"aripiprazole lauroxil","genericName":"aripiprazole lauroxil","approvalYear":"2015","relationship":"same-target"},{"drugId":"armodafinil","brandName":"armodafinil","genericName":"armodafinil","approvalYear":"2007","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"Q88T5P3444","CHEBI":"CHEBI:31899","INN_ID":"6430","UMLSCUI":"C0217937","ChEMBL_ID":"CHEMBL274491","KEGG_DRUG":"D01468","PDB_CHEM_ID":" AQD","PUBCHEM_CID":"156333","IUPHAR_LIGAND_ID":"983","MESH_SUPPLEMENTAL_RECORD_UI":"C030265"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":143,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Jan 24","pmid":"39856236","title":"Exploring the impact of deleterious missense nonsynonymous single nucleotide polymorphisms in the DRD4 gene using computational approaches.","journal":"Scientific reports"},{"date":"2024 Dec","pmid":"39341503","title":"Effects of dopamine receptor antagonists and radiation on mouse neural stem/progenitor cells.","journal":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology"},{"date":"2023 Jan 20","pmid":"36712018","title":"Effects of Dopamine Receptor Antagonists and Radiation on Mouse Neural Stem/Progenitor Cells.","journal":"bioRxiv : the preprint server for biology"},{"date":"2023 Apr","pmid":"36637685","title":"Agonistic properties of a series of psychotropic drugs at 5-HT(1A) receptors in rat and human brain membranes determined by [(35)S]GTPγS binding assay.","journal":"Pharmacological reports : PR"},{"date":"2022 Jun 15","pmid":"35545150","title":"Interaction of the preferential D(3) agonist (+)PHNO with dopamine D(3)-D(2) receptor heterodimers and diverse classes of monoamine receptor: relevance for PET imaging.","journal":"European journal of pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Emonapride is a small molecule. Its mechanism of action is not specified in the provided information.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}